ArticleCancer cell2017
Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once!
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution.NPJ precision oncology · 2026Article
- Article
- Article
- Paraganglioma and phaeochromocytoma in adult Fontan patients.Journal of medical imaging and radiation oncology · 2025Article
- The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease.Endocrine pathology · 2024Review
- Total loss ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Molecular Genetics of Pheochromocytoma/Paraganglioma.Current opinion in endocrine and metabolic research · 2024Article
- Pitfalls in the Diagnostic Evaluation of Pheochromocytomas.Journal of the Endocrine Society · 2024Article
- Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.International journal of molecular sciences · 2023Review
- Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.Nature communications · 2023Article
- Tumor hypoxia: From basic knowledge to therapeutic implications.Seminars in cancer biology · 2023Review
- Integrated proteogenomic characterization of medullary thyroid carcinoma.Cell discovery · 2022Article
- Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.The Journal of clinical investigation · 2022Review
- A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions.Cell reports. Medicine · 2022Article
- THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.Transactions of the American Clinical and Climatological Association · 2022Article
- Atypical variant takotsubo cardiomyopathy secondary to pheochromocytoma.Proceedings (Baylor University. Medical Center) · 2022Article
- Co-occurrence ofFrontiers in oncology · 2022Article
- Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers.Cancers · 2021Review
- Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data.Cancers · 2021Article
- What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?Endocrine pathology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
Pheochromocytomas and paragangliomas are infrequent, genetically heterogeneous neuroendocrine tumors. In this issue of Cancer Cell, Fishbein et al. report novel driver genes, pathogenic mechanisms, and markers of malignancy. Notably, the new findings support the long-held view that these tumors distinctively arise from a single driver event, either inherited or acquired.
Indexed as
Identifiers
28196587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.